Yamanouchi Pharmaceutical Co. has signed a five-year contract with Celera Genomics for access to its genomic and biological databases, the U.S. biotechnology firm said Monday.
Celera said the contract will allow the Japanese drugmaker to access its Web-based Celera Discovery System and enable it to develop drugs with greater efficiency.
The financial terms of the contract were not announced.
Yamanouchi is the second Japanese company to sign a database access contract with Celera. The private firm, based in Rockville, Md., completed the human genetic map last year.
Takeda Chemical Industries concluded a similar deal with Celera in March 2000.